SetPoint Medical is a developer of novel therapies and treatments for chronic autoimmune conditions through the Neuroimmune Modulation approach.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/19/2023 | Series C | $80MM | $xx.xx | $274.57MM | Action Potential Venture Capital, Ascendum Capital, Boston Scientific, Catalio Capital Management, Citta Capital, Euclidean Capital, Gilmartin Capital, Midas Capital, Morgenthaler Ventures, New Enterprise Associates, Norwest Venture Partners, Richard King Mellon Foundation, Shangbay Capital, Sve Capital, Topspin Fund, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
59,298,778
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Action Potential Venture Capital, Ascendum Capital, Boston Scientific, Catalio Capital Management, Citta Capital, Euclidean Capital, Gilmartin Capital, Midas Capital, Morgenthaler Ventures, New Enterprise Associates, Norwest Venture Partners, Richard King Mellon Foundation, Shangbay Capital, Sve Capital, Topspin Fund, Viking Global Investors
|
||||||
01/27/2021 | Series B | $65.41MM | $xx.xx | $144.02MM | Action Potential Venture Capital, Aethan Capital, Asahi Kasei, Ascendum Capital, Boston Scientific, Bpc Fund, Catalio Capital Management, Citta Capital, Euclidean Capital, Midas Capital, Morgenthaler, New Enterprise Associates, Revelation Partners, Richard King Mellon Foundation, Shangbay Capital, Sve Capital, Topspin Fund | |
Price per Share
$xx.xx
Shares Outstanding
65,407,963
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Action Potential Venture Capital, Aethan Capital, Asahi Kasei, Ascendum Capital, Boston Scientific, Bpc Fund, Catalio Capital Management, Citta Capital, Euclidean Capital, Midas Capital, Morgenthaler, New Enterprise Associates, Revelation Partners, Richard King Mellon Foundation, Shangbay Capital, Sve Capital, Topspin Fund
|
||||||
09/18/2019 | Series A | $42.6MM | $xx.xx | $60.86MM | Action Potential Venture Capital Limited, Boston Scientific, Morgenthaler Ventures, New Enterprise Associates, Topspin Partners | |
Price per Share
$xx.xx
Shares Outstanding
42,604,328
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Action Potential Venture Capital Limited, Boston Scientific, Morgenthaler Ventures, New Enterprise Associates, Topspin Partners
|